Closing the loop: eliminating open handling risks in CGT manufacturing

Thursday 08:00 PDT / 11:00 EDT / 16:00 BST / 17:00 CEST

Sponsor

Closing the loop: eliminating open handling risks in CGT manufacturing

Join leading experts from Ossium Health, CTMC, and BioLife Solutions, as they share actionable insights to enhance aseptic assurance, simplify facility design, and reduce operational complexity.

Understand how traditional handling methods introduce unnecessary contamination risk and regulatory complexity into your workflows, then discover proven strategies to achieve fully closed, sterile operations from cell thaw to final product. You'll learn from real-world CDMO experience of implementing closed-system solutions and gain access to performance data from large-scale testing to support your internal decision-making.

This session will show you how to reduce or eliminate reliance on biosafety cabinets in your manufacturing operations while simplifying cleanroom design and cutting operating costs through strategic container selection.

This webinar will equip you to:

Evaluate your current container strategy for open vs. closed risk points
Assess opportunities to reduce or eliminate biosafety cabinet dependence
Incorporate closed system-compatible automation tools into your technology stack
Benchmark CDMO-scale performance data to quantify the benefits of closed systems for your workflow

Erik Woods

Executive Vice President and Chief Science Officer at Ossium Health

Erik Woods, PhD, is the Executive Vice President and Chief Science Officer at Ossium Health and a recognized leader in cell therapy and biopreservation. With over two decades of experience, Dr.Woods has significantly advanced the fields of cryopreservation, cell manufacturing, and regenerative medicine. He has held leadership roles in both academia and industry, driving innovation in preservation technologies and process optimization for cell and gene therapies. His work has shaped best practices in cell storage, transport, and viability, directly influencing the delivery of advanced therapies to patients. A passionate advocate for scientific collaboration, Dr.Woods continues to shape the future of cell-based medicine through research, development, and industry partnership.

Sean Werner

Chief Technology Officer at BioLife Solutions

Sean Werner is the Chief Technology Officer at BioLife Solutions, where he oversees scientific and technical strategy for the company’s biopreservation and cell processing platforms. With over 20 years of experience in biologics and cell therapy technologies, Sean has led the development and commercialization of closed-system solutions that enable safe, scalable manufacturing of advanced therapies.

Jon Pileggi

Associate Director of Process Development at CTMC

Jon Pileggi leads the process development team at CTMC, a joint venture between MD Anderson and National Resilience. He brings deep expertise in scaling up cell therapy processes and has overseen critical initiatives to implement fully closed, GMP-compliant manufacturing. He recently led a study evaluating the CellSeal platform as a standard solution to eliminate biosafety cabinet reliance in CAR-T workflows.

You have registered for this webinar